Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | July 31, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date July 31, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,252 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745 Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0 F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 1,507 |
Reported balance
After 2024-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 121 | $22.20 | $2,685.93 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.16 to $22.205, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,625 | $21.41 | $34,795.64 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.02 to $21.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,452 | $20.39 | $90,754.47 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,746 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 6,198 | $2.14 | $13,263.72 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,798 Underlying: Common Stock · 1,800 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,800 | $20.10 | $36,171.90 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.406, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,800 | $2.14 | $3,852.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,598 Underlying: Common Stock · 14,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 14,000 | $17.91 | $250,677.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.49 to $18.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 14,000 | $2.14 | $29,960.00 |
DisclosureSEC source: 0001415889-22-011356 · form4-11142022_051101.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,373 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · derivative · entry 13 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,598 Underlying: Common Stock · 8,373 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F10 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,373 | $18.09 | $151,457.52 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.555 to $18.510, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 8,373 | $2.14 | $17,918.22 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,195 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · derivative · entry 12 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,971 Underlying: Common Stock · 14,195 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F10 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · derivative · entry 11 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,533 Underlying: Common Stock · 1,019 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F9 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,643 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,677 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,660 | $20.24 | $33,594.25 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.11 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,486 | $19.57 | $29,080.87 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.10 to $20.07, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,359 | $18.58 | $62,399.47 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,146 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $19.01, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,122 | $17.79 | $197,819.23 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,505 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.055 to $18.05, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,214 | $2.14 | $32,557.96 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,413 | $1.74 | $4,198.62 |
DisclosureSEC source: 0001415889-22-011245 · form4-11092022_051101.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,705 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010741 · form4-10202022_051001.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,166 Underlying: Common Stock · 5,705 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,705 | $21.08 | $120,286.50 |
DisclosureSEC source: 0001415889-22-010741 · form4-10202022_051001.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.665 to $21.355, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 5,705 | $2.14 | $12,208.70 |
DisclosureSEC source: 0001415889-22-010741 · form4-10202022_051001.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,871 Underlying: Common Stock · 4,185 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,185 | $20.16 | $84,379.64 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.602, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,185 | $2.14 | $8,955.90 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 110 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,056 Underlying: Common Stock · 110 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 110 | $20.05 | $2,205.50 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 17:01 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 110 | $2.14 | $235.40 |
DisclosureSEC source: 0001415889-22-010651 · form4-10182022_051001.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,954 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010479 · form4-10122022_051002.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,166 Underlying: Common Stock · 4,954 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,430 | $17.27 | $24,688.95 |
DisclosureSEC source: 0001415889-22-010479 · form4-10122022_051002.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.01 to $17.735, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,524 | $16.74 | $58,992.11 |
DisclosureSEC source: 0001415889-22-010479 · form4-10122022_051002.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.99, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,954 | $2.14 | $10,601.56 |
DisclosureSEC source: 0001415889-22-010479 · form4-10122022_051002.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,520 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · derivative · entry 13 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,120 Underlying: Common Stock · 10,520 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F10 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,757 | $16.41 | $28,828.15 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.34 to $16.52, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,763 | $15.93 | $139,631.39 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.33 to $16.33, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,520 | $2.14 | $22,512.80 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,281 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · derivative · entry 12 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,640 Underlying: Common Stock · 4,281 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F10 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,348 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · derivative · entry 11 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,552 Underlying: Common Stock · 6,348 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F9 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,506 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 1,506 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 948 | $17.31 | $16,410.64 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.095 to $16.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 882 | $16.54 | $14,588.63 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.095 to $16.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,210 | $15.64 | $175,344.58 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.095 to $16.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,629 | $2.14 | $22,746.06 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 17:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,411 | $1.74 | $4,195.14 |
DisclosureSEC source: 0001415889-22-010429 · form4-10112022_051001.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 17:15 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,520 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-009612 · form4-09142022_050901.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,900 Underlying: Common Stock · 7,520 shares Expires 2031-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.